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Early Response to Immunosuppressive Therapy Predicts
Good Renal Outcome in Lupus Nephritis
Lessons From Long-Term Followup of Patients in the Euro-Lupus Nephritis Trial
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Objective. In the Euro-Lupus Nephritis Trial
(ELNT), 90 patients with lupus nephritis were randomly
assigned to a high-dose intravenous cyclophosphamide
(IV CYC) regimen (6 monthly pulses and 2 quarterly
pulses with escalating doses) or a low-dose IV CYC
regimen (6 pulses of 500 mg given at intervals of 2
weeks), each of which was followed by azathioprine
(AZA). After a median followup of 41 months, a differ-
ence in efficacy between the 2 regimens was not ob-
served. The present analysis was undertaken to extend
the followup and to identify prognostic factors.
Methods. Renal function was prospectively as-
sessed quarterly in all 90 patients except 5 who were lost
to followup. Survival curves were derived using the
Kaplan-Meier method.
Results. After a median followup of 73 months,
there was no significant difference in the cumulative
probability of end-stage renal disease or doubling of the
serum creatinine level in patients who received the
low-dose IV CYC regimen versus those who received the
high-dose regimen. At long-term followup, 18 patients (8
receiving low-dose and 10 receiving high-dose treat-
ment) had developed permanent renal impairment and
were classified as having poor long-term renal outcome.
We demonstrated by multivariate analysis that early
response to therapy at 6 months (defined as a decrease
in serum creatinine level and proteinuria <1 gm/24
hours) was the best predictor of good long-term renal
outcome.
Conclusion. Long-term followup of patients from
the ELNT confirms that, in lupus nephritis, a
remission-inducing regimen of low-dose IV CYC fol-
lowed by AZA achieves clinical results comparable with
those obtained with a high-dose regimen. Early response
to therapy is predictive of good long-term renal out-
come.
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The pioneering studies by investigators at the
National Institutes of Health (NIH) have demonstrated
the importance of intravenous cyclophosphamide (IV
CYC) in the management of lupus nephritis (1–4),
although the optimal immunosuppressive regimen has
not been clearly established. Among other issues, the
dosage and the duration of CYC therapy are debated, in
particular given the potential side effects of CYC.
In the Euro-Lupus Nephritis Trial (ELNT), a
multicenter prospective study, we tested the hypothesis
that good long-term clinical results could be achieved
using lower doses of IV CYC than those prescribed in
the classic NIH regimen. By minimization, we randomly
assigned lupus patients with biopsy-proven proliferative
glomerulonephritis to receive a low-dose IV CYC regi-
men (6 pulses at a fixed dose of 500 mg, given at 2-week
intervals) or a high-dose IV CYC regimen (6 monthly
pulses and 2 quarterly pulses with escalating doses); in
both the low-dose and the high-dose regimens, the IV
CYC treatment course was followed by treatment with
azathioprine (AZA), used as remission-maintaining
therapy. After a median followup of 41 months, there
was no significant difference in efficacy between the 2
groups (5).
In the study reported herein, we extended the
analysis over a longer-term followup of the patients in
the 2 treatment groups in the ELNT. We identified
prognostic factors for long-term renal outcome, with
special emphasis on the kinetics of the initial response to
immunosuppressive therapy.
PATIENTS AND METHODS
Patient selection. Between September 1996 and Sep-
tember 2000, 90 patients with systemic lupus erythematosus
according to the American College of Rheumatology criteria
(6), who were age 14 years or older and had biopsy-proven
proliferative lupus glomerulonephritis (World Health Organi-
zation class III, IV, Vc, or Vd) and proteinuria (500 mg/24
hours), were enrolled in the ELNT at 19 centers in Europe.
Inclusion and exclusion criteria have been described elsewhere
(5). Of the 90 patients, 20 (22%) presented with renal impair-
ment and 25 (28%) with nephrotic syndrome. The study was
approved by the ethics committees of each participating hos-
pital, and written informed consent was obtained from all
patients.
Treatment. All patients received 3 IV pulses of 750 mg
methylprednisolone (1 per day on 3 successive days), followed
by oral glucocorticoid therapy at an initial dosage of 0.5 mg
prednisolone equivalent /kg/day for 4 weeks. A dosage of 1
mg/kg/day was allowed in critically ill patients (renal impair-
ment or severe extrarenal disease). After 4 weeks, glucocorti-
coid treatment was tapered by 2.5 mg prednisolone equivalent
every 2 weeks. Low-dose glucocorticoid therapy (5–7.5 mg
prednisolone/day) was maintained at least until month 30 after
enrollment and could be stopped thereafter at the discretion of
the treating physicians.
All patients received IV CYC therapy beginning on the
day of enrollment. They were randomized into 2 groups,
high-dose or low-dose IV CYC treatment, by minimization (7).
Patients assigned to the high-dose group received 8 IV CYC
pulses within 1 year, i.e., 6 monthly pulses followed by 2
quarterly pulses. The initial CYC dose was 0.5 gm/m2 of body
surface area, and the subsequent doses were increased by 250
mg according to the white blood cell count nadir measured on
day 14 (8), with a maximum of 1,500 mg per pulse. Patients
assigned to the low-dose group received 6 IV CYC pulses at a
fixed dose of 500 mg, in 2-week intervals. The use of mesna was
left to the decision of the physician. In both treatment groups,
AZA (2 mg/kg/day) was started 2 weeks after the last CYC
injection and continued until at least month 30 after enroll-
ment. Hypertension (diastolic blood pressure 90 mm Hg)
was treated initially with angiotensin-converting enzyme inhib-
itors (ACE inhibitors), unless they were contraindicated. The
introduction of ACE inhibitors was not allowed as antiprotein-
uric therapy within the first 6 months in normotensive patients.
Contraception was prescribed in all fertile, sexually active
women, and they were warned about the potential deleterious
effect that pregnancy could have on their disease, at least
during the first 30 months after study enrollment.
End points. Renal function (based on serum creatinine
level) was assessed on a regular basis (i.e., quarterly) in all 90
patients except 5 who were lost to followup. The median
duration of followup was 73 months.
Paraffin-embedded kidney biopsy specimens obtained
at baseline were reviewed by one of the authors (J-PC), who
was blinded to the randomization and outcome data and who
evaluated the specimens for activity and chronicity indices
according to the method of Morel-Maroger et al (9), as
described elsewhere (5). In some patients, repeat biopsies had
been performed, and these specimens were similarly reviewed.
Statistical analysis. Survival curves were derived using
the Kaplan-Meier method and were statistically tested by log
rank test. We calculated hazard ratios and their 95% confi-
dence intervals using the univariate Cox proportional hazards
model. Patients who were withdrawn from the trial were
included in Kaplan-Meier analyses (intent-to-treat analyses).
Within-group P values were calculated by repeated-measures
analysis of variance. Between-group P values were calculated
by analysis of covariance with adjustment for baseline values.
Logistic regression analysis was used for multivariate analysis
of outcome predictors. Unpaired t-tests, Wilcoxon’s signed
rank tests, chi-square tests, and Fisher’s exact tests were used
as appropriate.
RESULTS
Long-term followup of patients in the Euro-
Lupus Nephritis Trial. Of the 90 patients randomized in
the ELNT, 5 were lost to followup. Serum creatinine
values were obtained on a regular basis in the 85
remaining patients. After a median followup period of
73 months, renal function was permanently impaired at
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last followup in 21% of the patients (20% in the
low-dose group and 23% in the high-dose group), as
indicated in Table 1. The Kaplan-Meier curves shown in
Figure 1 indicate that there was no greater cumulative
probability of ESRD (Figure 1A) or doubling of the
serum creatinine value (Figure 1B) in patients receiving
the low-dose IV CYC regimen than in those given the
high-dose IV CYC regimen.
Three of the 85 patients for whom long-term
followup data were available had died: the first died of
multiorgan failure at month 1, the second died of an
unrelated cause (breast cancer) at month 43, and the
third died of septic shock at month 53 (7 months after
having received immunoablative doses of CYC, after
withdrawal from the ELNT). All 3 of these patients had
been initially randomized to the low-dose CYC group.
Since renal function data had been recorded shortly
before their deaths, they were included in the long-term
renal outcome analysis.
At 5 of the study centers, the local ethics com-
mittee approved performance of repeat kidney biopsies.
Thus, a second renal biopsy specimen was obtained from
20 patients (11 in the low-dose group and 9 in the
high-dose group), after a mean  SD followup time of
27  7 months. The mean  SD activity index score
declined significantly between the baseline and the
followup biopsies, in both the low-dose group (from
13.0  5.3 to 4.6  6.1; P  0.005 by Wilcoxon’s signed
rank test) and the high-dose group (from 10.3  7.4 to
2.4  1.1; P  0.011). In contrast, the chronicity index
score did not increase significantly between the baseline
and followup biopsies in either the low-dose group (from
0.8  1.0 to 1.1  1.1) or the high-dose group (from
0.7  0.7 to 0.6  0.9).
Prognostic factors. Patients were classified as
having good (n  67) or poor (n  18) long-term renal
outcome based on normal or repeatedly impaired serum
creatinine values at last followup. As indicated in Table
2, baseline clinical, biologic, and pathologic data did not
differ between good and poor long-term renal respond-
ers, except for the higher serum creatinine values in
patients with a poor outcome.
We next analyzed whether the kinetics of the
response within the first 6 months of therapy differed
between the 2 long-term renal outcome groups. Inter-
estingly, as indicated in Table 3, serum creatinine levels,
serum albumin levels, and proteinuria had improved
significantly more during the first 6 months of therapy in
the group with good long-term renal outcome. In con-
trast, scores on the European Consensus Lupus Activity
Measure (10) and serum C3 titers had improved simi-
Figure 1. Kaplan-Meier curves of the probability of absence of end-
stage renal disease (ESRD) (A) or of doubling of the serum creatinine
value (DSC) (B). Patients were randomized to receive a low-dose (LD)
regimen (circles) or a high-dose (HD) regimen (squares) of intrave-
nous cyclophosphamide, followed by azathioprine. Survival curves
were tested statistically by log rank test. In the low-dose group, the
hazard ratio was 0.35 (95% confidence interval 0.04–3.37) for ESRD
and 2.2 (95% confidence interval 0.66–7.27) for DSC. Numbers along
the abscissa are the number of patients at risk at each time point.
Analysis was by intent-to-treat.
Table 1. Renal function at last followup, by treatment group*
Renal function
All patients
(n  85)
High-dose IV
CYC group
(n  44)
Low-dose IV
CYC group
(n  41)
Normal 67 34 33
Permanently
impaired
18 10 8
End-stage renal
disease
4 3 1
Doubling of serum
creatinine
8 1 7
Impaired renal
function without
doubling of
serum creatinine
6 6 0
* Permanently impaired renal function was defined as a serum creat-
inine value that was repeatedly 1.4 mg/dl. IV CYC  intravenous
cyclophosphamide.
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larly in the 2 groups. The between-group differences for
serum albumin and 24-hour urinary protein levels re-
mained statistically significant when corrected (by ana-
lysis of covariance) for baseline serum creatinine values
(P  0.017 and P  0.0001 for serum albumin at 3
months and 6 months, respectively; P  0.018 and P 
0.011 for 24-hour urinary protein at 3 months and 6
months, respectively).
The percentage of patients whose 24-hour uri-
nary protein value was reduced by at least 50% or by at
least 75% at 6 months was significantly higher in the
good long-term renal outcome group than in the poor
Table 2. Baseline data in the 2 renal outcome groups*
Good long-term
renal outcome group
Poor long-term
renal outcome group P
Serum creatinine, mg/dl 1.09 0.54 1.47 0.97 0.03
Serum albumin, gm/dl 3.08 0.60 2.94 0.56 0.36
24-hour urinary protein, gm 3.03 2.49 3.23 2.25 0.76
Serum C3, mg/dl 56  25 54 21 0.80
ECLAM score 6.95 2.08 6.06 1.55 0.09
Systolic BP, mm Hg 134  22 136 20 0.83
Diastolic BP, mm Hg 83  16 84  17 0.88
Activity index score 9.6 6.2 11.5 5.7 0.24
Chronicity index score 0.8 0.9 0.9 0.7 0.47
WHO class III/IV/V, no. 13/46/5 4/11/3 0.50
* Between-group P values were calculated by chi-square test for World Health Organization (WHO) class
and by unpaired t-test for other parameters. Activity and chronicity index scores were calculated as
described in refs. 5 and 9. Except where indicated otherwise, values are the mean  SD. ECLAM 
European Consensus Lupus Activity Measurement; BP  blood pressure.
Table 3. Kinetics of response in the good and poor long-term renal outcome groups*
Parameter, time
Good long-term
renal outcome group,
mean  SD
Poor long-term
renal outcome group,
mean  SD Between-group P
Serum creatinine, mg/dl
Baseline 1.09  0.54 1.47 0.97
Month 3 0.92  0.22 1.11 0.27 0.028
Month 6 0.89  0.24 1.12 0.22 0.005
Within-group P 0.0009 0.161
Serum albumin, gm/dl
Baseline 3.08 0.60 2.94  0.56
Month 3 3.79 0.51 3.44  0.55 0.009
Month 6 3.99 0.48 3.42  0.47 0.000
Within-group P 0.0001 0.0005
24-hour urinary protein, gm
Baseline 3.03  2.49 3.23 2.25
Month 3 1.48  1.28 3.59 3.79 0.115
Month 6 1.15  1.41 2.55 2.67 0.026
Within-group P 0.0001 0.154
ECLAM score
Baseline 6.95  2.08 6.06 1.55
Month 3 2.39  1.75 2.29 1.40 0.974
Month 6 1.84 1.57 2.18  1.33 0.262
Within-group P 0.0001 0.0001
Serum C3, mg/dl
Baseline 56 25 54  21
Month 3 86  26 80 19 0.378
Month 6 86  22 79 27 0.313
Within-group P 0.0001 0.0002
* Within-group P values were calculated by repeated-measures analysis of variance. Between-group P
values were calculated by analysis of covariance, after adjustment for the baseline value of the tested
parameter. ECLAM  European Consensus Lupus Activity Measurement.
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long-term renal outcome group (Figure 2). The positive
predictive value of a 75% decrease in proteinuria at 6
months for good long-term renal outcome was 90%.
Similar results were obtained when absolute levels of
improvement were analyzed: the positive predictive
value of a 24-hour urinary protein level 1 gm at 6
months for good long-term renal outcome was 87%.
Importantly, the use of ACE inhibitors within the first 6
months of therapy did not differ between patients who
did and those who did not experience a 75% decrease in
proteinuria at 6 months (31% and 38%, respectively),
thereby reducing the risk of bias linked to early ACE
inhibitor use.
To complete the study of predictors of long-term
renal outcome, we performed a multivariate analysis
using a logistic regression model. As indicated in Table
4, of the 13 covariates tested, only a decrease in the
serum creatinine value at 6 months and a 24-hour
urinary protein level of 1 gm at 6 months were
predictors of good long-term renal outcome. Interest-
ingly, none of the baseline parameters had such a
predictive value. A subset analysis performed on pa-
tients with baseline renal impairment (serum creatinine
1.4 mg/dl) for whom kinetics data and long-term renal
outcome were known indicated a similar trend, namely,
that early response to therapy had prognostic value
(Table 5).
DISCUSSION
The prospective data presented here confirm that
good long-term results in patients with proliferative
lupus glomerulonephritis can be achieved by remission-
inducing therapy with a low-dose IV CYC regimen
(cumulative dose 3 gm) followed by AZA as remission-
maintaining treatment. Of note, only 1 patient of the 44
randomized to receive this regimen (now referred to as
the Euro-Lupus regimen) had developed ESRD after a
followup of 6 years. Whether these results can be
extrapolated at 10 years is obviously speculative. How-
Figure 2. Percentage of patients in the good long-term renal outcome
group and the poor long-term renal outcome group who had at least a
50% reduction or at least a 75% reduction in 24-hour urinary protein
levels at 6 months. P values were calculated by Fisher’s exact test.
Table 4. Multivariate analysis of predictors of good long-term renal outcome*
Variable P Odds ratio 95% confidence interval
Age (30 years) 0.99 1.0 0.2–5.1
Sex (female) 0.98 0 NA
Baseline diastolic pressure (90 mm Hg) 0.77 1.3 0.3–5.9
Baseline serum creatinine (1.4 mg/dl) 0.06 7.7 0.9–65.6
Baseline serum albumin (3 gm/dl) 0.31 0.4 0.1–2.2
Baseline 24-hour urinary protein (3 gm) 0.81 0.8 0.1–4.6
WHO class (III or Vc) 0.32 0.3 0–3.4
Activity index (10) 0.53 2.0 0.2–18.4
Chronicity index (1) 0.11 4.0 0.7–21.9
Treatment allocation (high-dose IV CYC) 0.33 0.4 0.1–2.3
ACE inhibitor use (yes) 0.34 2.3 0.4–12.5
Serum creatinine at 6 months (decreased) 0.01 14.9 2.0–111.8
24-hour urinary protein at 6 months (1 gm) 0.03 6.3 1.2–34.4
* The analysis was performed using a logistic regression model. NA  not applicable; WHO 
World-Health Organization; IV CYC  intravenous cyclophosphamide; ACE inhibitor  angiotensin-
converting enzyme inhibitor.
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ever, based on the number of patients in both groups
who had developed impaired renal function after the
long-term followup reported here (20% and 23% in the
low-dose group and the high-dose group, respectively), it
is unlikely that further followup will reveal a difference.
In a previous report (5), we had already shown that
episodes of severe infection were less than half as
common in patients given a low-dose IV CYC regimen
(7 episodes, versus 17 in the high-dose group), although
this difference was not statistically significant. From
those results taken together with the findings reported
herein, we propose that the Euro-Lupus regimen is a
suitable alternative to a regimen of long-term, high-dose
IV CYC, at least for European patients. Our results are
consistent with those described in a recent report by
Contreras et al indicating that short-term therapy with
IV CYC followed by maintenance therapy with AZA or
mycophenolate mofetil (MMF) is safer—and even more
efficacious—than long-term therapy with IV CYC (11),
although some caveats can be raised (12).
The present analysis was also aimed at identifying
prognostic factors in lupus glomerulonephritis. Many
reports (13–17) have already described factors that are
associated with poor prognosis, including young age at
onset of nephritis, African American ethnicity, hyper-
tension and renal impairment at baseline, and poor
pathologic findings on kidney biopsy, such as the pres-
ence of cellular crescents in 50% of the glomeruli or
an elevated chronicity index related to interstitial and/or
glomerular fibrosis. It should be stressed, however, that
most of these studies were retrospective.
Only a few studies have analyzed whether the
initial response to therapy predicts long-term renal
outcome. Levey et al found that treatment response,
defined as resolution of an initial serum creatinine
elevation within 48 weeks, was prognostic in a cohort of
63 patients with severe, glucocorticoid and oral CYC–
treated lupus nephritis in the Lupus Nephritis Collabo-
rative Study (18). Laitman and colleagues, in a study that
included a relatively small number of patients (n  39),
showed that patients whose serum CH50 titers were
consistently normal had better outcome than those in
whom CH50 values were found to be normal only
transiently or not at all (19). In the present study we
have convincingly demonstrated by multivariate analysis
that an early response to therapy at 6 months (decrease
in the serum creatinine level and a 24-hour urinary
protein level 1 gm) is the best predictor of good
long-term renal outcome, compared with all baseline
parameters tested as other covariates. These prospec-
tively obtained data confirm the findings obtained by
Fraenkel et al in a study using data that were accumu-
lated retrospectively (20). Those investigators reported
that change in proteinuria at 1 year was a powerful
predictor of long-term outcome in a group of 85 patients
who had received various immunosuppressive regimens.
Whether the length and intensity of immunosup-
pression should be tailored according to the initial
Table 5. Kinetics of response: subset analysis restricted to patients presenting with renal impairment at
baseline*
Parameter, time
Good long-term
renal outcome group,
mean  SD
Poor long-term
renal outcome group,
mean  SD Between-group P
Serum creatinine, mg/dl
Baseline 2.05  0.70 2.42 1.22
Month 3 1.07  0.30 1.37 0.29 0.141
Month 6 1.04  0.27 1.28 0.33 0.186
Within-group P 0.0002 0.089
Serum albumin, gm/dl
Baseline 2.88 0.43 2.74  0.46
Month 3 3.79 0.44 3.33  0.75 0.040
Month 6 4.03 0.59 3.32  0.43 0.046
Within-group P 0.0001 0.208
24-hour urinary protein, gm
Baseline 2.61  1.50 4.92 2.49
Month 3 1.58  1.52 5.93 5.11 0.092
Month 6 1.18  1.96 4.04  2.89 0.122
Within-group P 0.099 0.407
* Within-group P values were calculated by repeated-measures analysis of variance. Between-group P
values were calculated by analysis of covariance, after adjustment for the baseline value of the tested
parameter.
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response to therapy becomes a key issue not addressed
in the ELNT. Our results would suggest that a more
incisive strategy should be adopted for patients whose
proteinuria does not dramatically improve after 3 or 6
months of IV CYC therapy. In such patients, MMF
might be an option as rescue therapy. This immunosup-
pressive drug has become widely used in lupus nephritis
since the pioneering work of Chan et al, who demon-
strated its potential as remission-inducing therapy in a
short-term clinical trial in which it was compared with
oral CYC (21). In a recent trial (22), MMF was shown to
be superior to IV CYC as remission-inducing therapy,
although it should be stressed that only very short-term
responses have been evaluated to date.
Taken together, the data presented here confirm
that the Euro-Lupus regimen might offer an alternative
to the classic NIH regimen for the treatment of lupus
glomerulonephritis. Moreover, our results illustrate the
critical importance of early response to immunosuppres-
sive therapy.
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